LINGO1-targeted antibody-drug conjugates improve efficacy and tolerability of antineoplastic therapies in Ewing sarcoma models
Journal of Clinical Investigation · 03.08.2026 · 136 (15)
DOI: 10.1172/jci204641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.08.2026. Verfasst von Zhichuan Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Bone Neoplasms, Immunoconjugates, Membrane Proteins. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: North Carolina Biotechnology Center, U.S. Department of Defense.
Abstract (Originalsprache)
We reported LINGO1 as a potential marker on Ewing sarcoma cells that could enable targeted drug delivery, improving treatment effectiveness while reducing side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lineberger Comprehensive Cancer Center.
- Department of Biochemistry and Biophysics.
- Department of Biostatistics, and.
- Department of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Förderung
- North Carolina Biotechnology Center
- U.S. Department of Defense
Zitieren
APA
Zhu, Z., Liu, Y., Deng, Y., Li, Z., Baldwin, A. S., & Liu, P. (2026). LINGO1-targeted antibody-drug conjugates improve efficacy and tolerability of antineoplastic therapies in Ewing sarcoma models. Journal of Clinical Investigation, 136(15). https://doi.org/10.1172/jci204641
Vancouver
Zhu Z, Liu Y, Deng Y, Li Z, Baldwin AS, Liu P. LINGO1-targeted antibody-drug conjugates improve efficacy and tolerability of antineoplastic therapies in Ewing sarcoma models. Journal of Clinical Investigation. 2026;136(15). doi:10.1172/jci204641
BibTeX
@article{Zhu2026,
author = {Zhu, Zhichuan and Liu, Yusha and Deng, Yu and Li, Zhijun and Baldwin, Albert S and Liu, Pengda},
title = {LINGO1-targeted antibody-drug conjugates improve efficacy and tolerability of antineoplastic therapies in Ewing sarcoma models},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {15},
doi = {10.1172/jci204641}
}
EUVIMED